Myopia is a worldwide public health issue with increasing prevalence across many regions in the past decades, especially in East Asia.1, 2, 3 Myopic eyes undergo characteristic structural changes such as parapapillary atrophy (PPA),4 which increase the risk of sight-threatening complications.5 The parapapillary gamma zone, as part of PPA, refers to the region located at the optic disc border that is characterized by the absence of Bruch membrane.4,6, 7, 8 The presence and enlargement of the parapapillary gamma zone are related to various ocular conditions, including macular retinoschisis, myopic maculopathy progression, nonglaucomatous optic nerve atrophy, and visual field defects in individuals with high myopia.9, 10, 11, 12, 13 Besides, an enlarged gamma zone may represent a latent structural weakness within the optic nerve head (ONH). This deformation has been suggested to correlate with an increased susceptibility to glaucomatous stress in myopic eyes.14 Therefore, the development and enlargement of the parapapillary gamma zone may suggest an increased risk of future visual impairment resulting from myopia. However, research on intervention strategies aimed at reducing the development of parapapillary gamma zone is currently insufficient.
Low-concentration atropine eye drops have demonstrated efficacy in mitigating myopia progression and axial elongation.15, 16, 17, 18, 19, 20, 21, 22 Low-concentration Atropine for Myopia Progression (LAMP) studies highlighted a concentration-dependent response for low-concentration atropine drops in myopia control.22, 23, 24, 25 Despite these advancements, the efficacy of low-concentration atropine in mitigating the development of PPA, particularly in relation to the parapapillary gamma zone, has remained unknown. Recent studies suggested a strong correlation between parapapillary gamma zone development and excessive axial elongation.26,27 However, long axial length (AL) alone does not fully explain its presence. Epidemiological investigations also revealed the presence of gamma zone in nonmyopic eyes, suggesting that factors beyond axial elongation may influence its development.4,28 Thus, understanding the impact of atropine applied topically on the parapapillary gamma zone is of clinical importance.
If low-concentration atropine proves effective in curbing the enlargement of gamma zone, it may indicate a reduced risk of future myopia-related complications and enhanced visual outcomes for myopic children in their later life.
The present study aimed to assess the effects of topical low-concentration atropine eye drops on the parapapillary gamma zone among myopic children for 3 years, along with the LAMP study.
Methods
Study Design and Participants
This was a secondary analysis of the LAMP trial, a randomized, double-blinded, placebo-controlled trial. The design of the LAMP study has been described previously.22, 23, 24 In brief, children aged 4 to 12 years with a myopic refractive error of at least –1.0 diopter (D) in both eyes, astigmatism of <2.5 D, and documented myopic progression of ≥0.5 D in the previous year were enrolled in the LAMP trial. In phase I (i.e., the first study year), the children were randomly assigned to 4 treatment groups (0.05%, 0.025%, 0.01% topical atropine eye drops, and placebo eye drops).
In phase II (i.e., the second year), all children in the placebo group of phase I were switched over to receive 0.05% atropine eye drops at the beginning of the second year until the end of the fifth year. Children of the other 3 groups kept the original treatment. In phase III (i.e., the third year), the children in each of the 3 original treatment groups of phase II (0.05%, 0.025%, and 0.01% atropine eye drops) were randomized in a 1:1 ratio into (a) a continued treatment subgroup and (b) a treatment cessation subgroup.
For the continued treatment subgroups, the children continued receiving atropine eye drops of the same concentration once nightly in both eyes throughout the third year. For the treatment cessation subgroups, all individuals stopped receiving eye drops. In phase IV (i.e., years 4 and 5), all children in the atropine continued treatment groups of any concentration (0.05%, 0.025%, and 0.01% atropine) were switched to 0.05% atropine.
Meanwhile, children in treatment cessation groups of any previous atropine concentration (0.05%, 0.025%, and 0.01% atropine) were restarted on topical 0.05% atropine if either eye progressed in myopic refractive error of ≥0.50 D/year (pro re nata retreatment). If such progression was observed during year 3, treatment would be restarted at the start of year 4.
All parents or guardians gave written informed consent, with verbal assent from the children. The study is registered with the Chinese Clinical Trial Registry (identifier: ChiCTR-TRC-13004032) and the Clinical Trials Registry of the Centre for Clinical Research and Biostatistics, The Chinese University of Hong Kong (identifier: CUHK_CCT00383). It was approved by the ethics committee of The Chinese University of Hong Kong.
All procedures were conducted according to the tenets of the Declaration of Helsinki. The results were reported following the Consolidated Standards of Reporting Trials reporting guidelines.
Parapapillary Gamma Zone Measurement and Quality Control
The ONH was imaged by spectral-domain OCT (Spectralis-OCT, Heidelberg Engineering) using a scan protocol with 24 equally spaced radial B-scans, each in turn comprising 768 A-scans, covering a 15° region centered on the optic disc. Participants were followed up at 1-year intervals. Parapapillary gamma zone was defined as the parapapillary region without Bruch membrane, that is, the area between the border of Bruch membrane opening and the border of the optic disc.29 The parapapillary gamma zone was assessed across all 48 meridians of the 24 B-scans.
OCT images and cross-sectional B-scan images were independently evaluated by 2 trained readers (X.J.Z. and Y.L.). The demographics, ocular information, and treatment were masked during the grading process. Any discrepancies between the readers were resolved through discussions to achieve consensus.
In case of doubt, an experienced ophthalmologist (J.C.Y.) was consulted to help arbitrate the decisions. Images with significant image artifacts or image quality scores <15 were excluded from analysis. To evaluate the reproducibility of the measurements, both intragrader and intergrader reliability for gamma zone area measurements were assessed by computing the intraclass correlation coefficients from a randomly drawn sample of 50 OCT images manually delineated twice.
After the grading process, image magnification was corrected by the Littmann–Bennett method.28,30
Ocular Biometric Measures
Detailed ocular examinations have been described previously.31 Cycloplegic autorefractometry was performed using an autorefractor (Nidek ARK-510A) after applying a cycloplegic regime, which consisted of ≥2 cycles of eye drops. Two separate eye drops, cyclopentolate 1% (Cyclogyl; Alcon-Convreur) and tropicamide 1% (Santen), were administered to both eyes 5 minutes apart. A second cycle of the same cycloplegic eye drops was administered 10 minutes after the first cycle.
Ocular AL was measured by interferometry (Zeiss IOL Master, Carl Zeiss Meditec Inc). The refractive error expressed as spherical equivalent was calculated as spherical power of the refractive error plus half of the cylindrical power.
Parental Myopia, Outdoor Time, Near Work Time, and Treatment Compliance Measures
Parental myopia, outdoor time, near work time, and treatment compliance were assessed using the Chinese 25-Item Visual Function Questionnaire, along with the validated questionnaires that had been used in the Sydney Myopia Study and the Hong Kong Children Eye Study.3 Treatment compliance was classified according to the mean number of days per week that trial medication was used as reported by the subjects; compliance rates of >75% (i.e., a mean of 5.25 days/week) were considered acceptable.24
Outcome Measures
The primary outcomes of this study included (1) the differences in parapapillary gamma zone changes between the continued treatment and washout subgroups at each concentration over 3 years and (2) the associated factors with parapapillary gamma zone enlargement during treatment. While children from the LAMP study had been followed up for 5 years, all participants in the continued treatment groups from the originally studied concentration were switched to 0.05% atropine after the third year. This transition complicated the direct comparison of parapapillary gamma zone area enlargement among children treated with 0.05%, 0.025%, and 0.01% atropine eye drops over the course of 5 years.
To further corroborate the effect of atropine on gamma zone enlargement, we analyzed data from the 1-year, 2-year, and 5-year follow-up assessments and included the differences of 1-year, 2-year, and 5-year changes of gamma zone area among different treatment groups as secondary outcomes.
Statistical Analysis
Continuous variables were reported as means and standard deviations, and categorical variables were reported in frequencies and percentages. The analysis included data from both eyes of all participants. The size changes of the parapapillary gamma zone were calculated according to differences between baseline and designated follow-up visits.
The chi-square test and Fisher exact test were used to analyze group differences in categorical data. Generalized estimating equations with robust standard errors for longitudinal data analysis were applied to adjust for the correlation between eyes and to incorporate all relevant data. Two models were established to identify factors related to gamma zone area enlargement over 3 years.
Model 1 was adjusted for treatment group, treatment compliance, age, sex, baseline gamma zone area, and parental myopia. Model 2 additionally adjusted for changes in AL over 3 years. To test whether the changes of parapapillary gamma zone were attributable to axial elongation, mediation analysis was performed to estimate the direct effect of atropine treatment on gamma zone area changes, as well as the mediating effect through axial elongation.
All statistical analyses were performed using SPSS Statistics (version 27.0, IBM Corp). Two-tailed P values <0.05 were considered statistically significant.
Results
Participant Characteristics
Of 280 children who underwent ONH examination, 28 children were excluded due to incomplete data, and 14 children were excluded due to suboptimal image quality. Finally, a total of 238 children with qualified imaging data were included in this study. Of these, 192 children were retained at the 3-year follow-up assessment: 51 recived 0.05% atropine eye drops, 44 received 0.025% atropine eye drops, 53 received 0.01% atropine eye drops, and 44 received placebo eye drops (Fig S1, available at www.ophthalmologyscience.org).
Baseline demographics, gamma zone area, and ocular biometrics features were comparable among 0.05%, 0.025%, 0.01%, and switchover groups (Table 1). Participants included in this study were slightly older and exhibited longer AL at baseline compared with those who were excluded. Other characteristics of the included and excluded subjects were comparable.
Additionally, the baseline demographic and ocular features of children who completed 3 years of examinations were similar to those who did not (Tables S1 and S2, available at www.ophthalmologyscience.org). The intragrader and intergrader reliabilities for gamma zone measurement were excellent, with the intraclass correlation coefficients of 0.99 (0.89–1.00) and 0.97 (0.86–0.99).Table 1Demographics and Characteristics at Baseline in the 0.05% Atropine, 0.025% Atropine, 0.01% Atropine, and Switchover Groups That Have Completed 3 Yrs0.05% Atropine (N = 51)0.025% Atropine (N = 44)0.01% Atropine (N = 53)Switchover (N = 44)∗Continue (N = 27)Washout (N = 24)Continue (N = 25)Washout (N = 19)Continue (N = 24)Washout (N = 29)Age, mean (SD), yr9.27 (1.18)8.93 (1.93)9.01 (1.55)9.49 (1.38)9.04 (1.71)8.72 (1.65)9.19 (1.63)Sex, No. (%) Male13 (48.1%)14 (58.3%)14 (56.0%)9 (47.4%)11 (45.8%)19 (65.5%)20 (45.5%) Female14 (51.9%)10 (41.7%)11 (44.0%)10 (52.6%)13 (54.2%)10 (34.5%)24 (54.5%)BMI, mean (SD), kg/m216.78 (5.21)16.30 (1.90)16.57 (2.40)15.83 (1.45)15.97 (2.94)16.88 (2.68)16.06 (3.55)Axial length, mean (SD), mm25.05 (0.97)24.98 (1.00)25.11 (0.92)24.89 (0.81)24.64 (1.24)24.94 (1.09)25.07 (1.16)Spherical equivalent, mean (SD), D–4.36 (1.77)–4.23 (2.75)–4.55 (2.11)–3.54 (1.52)–4.01 (2.41)–4.21 (2.15)–4.55 (2.13)Gamma zone area, mean (SD), mm20.32 (0.29)0.33 (0.30)0.45 (0.31)0.37 (0.27)0.36 (0.29)0.40 (0.40)0.47 (0.35)Corneal thickness, mean (SD), μm549 (36)550 (32)548 (27)551 (34)545 (24)546 (29)548 (291)IOP, mean (SD), mmHg15.6 (2.1)15.3 (1.8)15.9 (1.4)16.6 (1.8)15.4 (1.8)15.4 (2.1)15.8 (2.2)Photopic pupil size, mean (SD), mm3.97 (0.63)3.74 (0.47)3.90 (0.82)3.58 (0.44)3.47 (0.43)3.62 (0.55)3.95 (0.86)Mesopic pupil size, mean (SD), mm6.92 (0.92)6.90 (0.47)6.84 (0.67)6.66 (0.58)6.50 (0.62)6.60 (0.66)6.68 (0.61)Accommodation amplitude, mean (SD), D13.5 (2.1)11.5 (3.0)12.3 (2.7)12.7 (2.4)11.5 (2.9)12.3 (3.0)11.7 (2.6)Distance VA, mean (SD), logMAR0.01 (0.07)0.03 (0.10)0.03 (0.08)0.00 (0.07)0.02 (0.05)0.02 (0.09)–0.01 (0.06)Near VA, mean (SD), logMAR0.01 (0.07)0.05 (0.21)0.04 (0.09)0.01 (0.12)0.03 (0.09)0.02 (0.14)0.02 (0.11)Outdoor activity,† mean (SD), hrs per day2.28 (0.84)2.32 (0.73)2.30 (0.60)2.13 (0.89)2.52 (0.67)2.37 (0.76)2.09 (0.69)Nearwork,‡ mean (SD), dioptic hrs per day15.79 (2.74)16.01 (4.59)16.49 (4.38)15.66 (4.00)15.86 (3.09)17.33 (3.37)16.63 (4.14)BMI = body mass index; D = diopter; IOP = intraocular pressure; logMAR = logarithm of the minimum angle of resolution; SD = standard deviation; VA = visual acuity.∗Subjects received a placebo during the first year and were then switched over to the 0.05% atropine group at the beginning of the second year.†Outdoor activity = outdoor exercise + outdoor leisure activity.‡Nearwork = 3∗(homework + reading + playing cell phone) + 2∗(using computer + playing video game) +1∗(watching TV).
Longitudinal Changes in Parapapillary Gamma Zone
Over the course of 3 years of continuous treatment, the cumulative mean gamma zone area enlargements were 0.09 ± 0.09 mm2, 0.19 ± 0.12 mm2, and 0.22 ± 0.17 mm2 for the 0.05%, 0.025%, and 0.01% atropine groups, respectively (Fig 1). Concentration-dependent effects were observed among continued treatment subgroups (overall P < 0.001, Table 2). Representative images illustrating parapapillary gamma zone enlargement for each group are presented in Figure 2.
In the washout subgroups, the cumulative mean gamma zone area enlargements were 0.13 ± 0.09 mm2, 0.20 ± 0.12 mm2, and 0.23 ± 0.15 mm2 for the 0.05%, 0.025%, and 0.01% groups, respectively, with significant differences among subgroups (P = 0.016). In the switch-over group, gamma zone area enlargement was 0.22 ± 0.14 mm2, which was significantly larger compared to the 0.09 ± 0.09 mm2 observed in the 0.05% continued group (P < 0.001) and the 0.13 ± 0.09 mm2 in the 0.05% washout group (P = 0.003) over 3 years.Figure 1Comparisons of gamma zone area changes over 3 years among different atropine groups. Children in each of the 3 original treatment groups (0.05%, 0.025%, and 0.01% atropine) were randomized on a 1:1 ratio into a continued treatment subgroup and a treatment cessation subgroup at the third year.
Switch-over group: placebo in the first year and switched over to the 0.05% atropine group at the beginning of the second year and continued 0.05% treatment in the third year.Table 2Accumulative Change in Gamma Zone Area over 3 Yrs in the 0.05% Atropine, 0.025% Atropine, 0.01% Atropine, and Switchover GroupsAccumulative Gamma Zone Area Change, Mean (SD), mm2(3) 0.05% Atropine(2) 0.025% Atropine(1) 0.01% Atropine(0) Switchover∗From baseline to1 yr0.05 (0.05)0.08 (0.07)0.10 (0.09)0.13 (0.08)2 yrs0.08 (0.08)0.14 (0.10)0.16 (0.12)0.18 (0.12)3 yrs(3a) Continue†(3b) Washout‡(2a) Continue†(2b) Washout‡(1a) Continue†(1b) Washout‡0.09 (0.09)0.13 (0.09)0.19 (0.12)0.20 (0.12)0.22 (0.17)0.23 (0.15)0.22 (0.14)P value§Overall (3a vs 2a, 3a vs 1a, 2a vs 1a), P for trend<0.001 (0.038, <0.001, 0.09), <0.0013a vs 0<0.001Overall (3b vs 2b, 3b vs 1b, 2b vs 1b), P for trend0.008 (0.020, 0.027, 0.97), 0.0163b vs 00.003SD = standard deviation.Values shown in bold indicate statistical significance at P < 0.05 (2‑sided tests).∗Subjects received a placebo during the first year and were then switched over to the 0.05% atropine group at the beginning of the second year.†Subjects in washout subgroups at any initial concentration (0.05%, 0.025%, and 0.01% atropine) stopped receiving eye drops.‡Subjects in continued subgroups continued receiving eye drops of the same concentration throughout the third year.§P values were generated by generalized estimating equation models with age, sex, baseline axial length, and baseline gamma zone area for gamma zone comparisons (Sequential Bonferroni).Figure 2Representative OCT images showing the development and enlargement of parapapillary gamma zone in different treatment groups over 3 years. The BMO was identified in 48 meridians. Parapapillary gamma zone was delineated by the area between the red dashed line and the navy blue dashed line in the infrared en face OCT image.
The green arrow indicates the direction of the corresponding OCT B-scan displayed below. The red arrow marks the BMO, and the navy blue arrow denotes the optic disc border. A1-A4 show an 8-year-old boy in the switchover group.
During the first year, while receiving placebo eye drops, the parapapillary gamma zone enlarged by 0.25 mm2. After the switch to 0.05% atropine in the second year, the rate of gamma zone enlargement markedly decreased. B1-B4 show a 7-year-old girl in the 0.01% atropine treatment group.
C1-C4 show an 8-year-old girl in the 0.025% atropine treatment group. D1-D4 show a 9-year-old boy in the 0.05% atropine treatment group, in which the parapapillary gamma zone remained stable over 3 years. BMO = Bruch membrane opening.
Concentration-dependent effects for an atropine-related reduction in gamma zone enlargement were also observed in year 1 and year 2 (Table S3, available at www.ophthalmologyscience.org). At the end of the first year of follow-up, gamma zone enlargement was significantly smaller in the groups under therapy with 0.05% atropine (0.05 ± 0.05 mm2, P < 0.001) and 0.025% atropine (0.08 ± 0.07 mm2, P = 0.006) as compared with the placebo group (0.13 ± 0.08 mm2), while the group under therapy with 0.01% atropine (0.10 ± 0.09 mm2, P = 0.06) did not differ significantly from the placebo group. At the end of the second year of follow-up, the mean gamma zone enlargement was 0.08 ± 0.08 mm2, 0.14 ± 0.10 mm2, and 0.16 ± 0.12 mm2 in the 0.05%, 0.025%, and 0.01% atropine groups, respectively (overall P < 0.001).
A similar pattern was observed after 5 years of follow-up in the continued treatment group. Over 5 years, the cumulative mean gamma zone area changes in the continued treatment groups were significantly different across the initial 0.05%, 0.025%, and 0.01% atropine subgroups (0.13 ± 0.15 mm2, 0.23 ± 0.14 mm2, and 0.26 ± 0.17 mm2, respectively, overall P = 0.001, Fig S2 and Table S4, available at www.ophthalmologyscience.org). The mean values of parapapillary gamma zone area and AL over 5 years are reported in Table S5 (available at www.ophthalmologyscience.org).
Associated Factors with Changes in the Parapapillary Gamma Zone
Over 3 years, the changes in parapapillary gamma zone area (with 1 mm2 changes representing a 1-unit change) followed a concentration-dependent response in the continued treatment group, with smaller gamma zone area enlargement at higher atropine concentrations (β = –0.06, P < 0.001) in model 1. In model 2, after further adjustment for AL changes, the enlargement of gamma zone areas was significantly associated with 0.05% atropine treatment (β = –0.07, P = 0.005), female sex (β = 0.05, P = 0.006), baseline gamma zone area (β = 0.23, P < 0.001), and AL change (β = 0.14, P < 0.001). However, there were no significant associations found with treatment compliance, age, or parental myopia (all P values >0.05, Table 3).
In the washout group, during the third year, we found that younger age (β = –0.01, P < 0.001), longer AL (β = 0.01, P = 0.013), and a larger gamma zone area (β = 0.03, P = 0.002) at treatment cessation were associated with larger rebound effect in gamma zone enlargement (Table S6, available at www.ophthalmologyscience.org).Table 3Factors Associated with Gamma Zone Change over 3 YrsFactorModel 1Model 2β (95% CI)P Valueβ (95% CI)P ValueContinue subgroup Treatment group–0.06 (–0.09 to –0.03)<0.001∗–0.04 (–0.06 to –0.01)0.005∗ 0.01% atropineReferenceReference 0.025% atropine–0.05 (–0.12 to 0.01)0.13–0.03 (–0.09 to 0.02)0.26 0.05% atropine–0.12 (–0.18 to –0.06)<0.001–0.07 (–0.12 to –0.02)0.005 Treatment compliance0.04 (–0.06 to 0.15)0.430.07 (–0.05 to 0.18)0.27 Age (yrs)–0.03 (–0.05 to –0.01)<0.001–0.01 (–0.02 to 0.01)0.32 Sex MaleReferenceReference Female0.06 (0.02–0.11)0.0050.05 (0.01–0.09)0.006 Baseline gamma zone area (mm2)0.24 (0.15–0.33)<0.0010.23 (0.15–0.30)<0.001 Parental myopia ≤1 with moderate or high myopiaReferenceReference Both with moderate or high myopia–0.02 (–0.06 to 0.03)0.50–0.01 (–0.05 to 0.03)0.57 Axial length change over 3 yrs (mm)0.14 (0.10–0.19)<0.001CI = confidence interval.Generalized estimating equations were used to adjust for the correlation between eyes.Model 1 adjusted for treatment group, treatment compliance, age, sex, baseline gamma zone area, and parental myopia; model 2 further adjusted for axial length change.Values shown in bold indicate statistical significance at P < 0.05 (2‑sided tests).∗P value for trend.
Mediation Analysis among Atropine Treatment, Axial Elongation, and Gamma Zone Enlargement
In the mediation analyses, using placebo as the reference group, both 0.05% atropine and 0.025% atropine showed significant direct effects on gamma zone change over the first year, accounting for 75.4% (β = –0.05, P < 0.001) and 67.5% (β = –0.03, P = 0.022) of the total effect (Fig 3). Axial length elongation partially mediated 24.6% (β = –0.02, P = 0.001) and 32.5% (β = –0.01, P = 0.010) of these associations.Figure 3Mediation analysis of atropine treatment (independent variable), AL elongation (mediator), and gamma zone area change (dependent variable) over the first year. (A) Comparisons of the effects of 0.05% atropine and placebo on changes in gamma zone area; (B) comparisons of the effects of 0.025% atropine and placebo on changes in gamma zone area; models adjusted for age, sex, baseline gamma zone area, and baseline AL.
AL = axial length.
Discussion
In this study, using data from the LAMP randomized controlled trial, we report for the first time the 3-year changes in parapapillary gamma zone among children receiving daily 0.05%, 0.025%, and 0.01% atropine eye drops. First, we found that changes in the gamma zone area followed a concentration-dependent manner over 3 years. Continuous treatment with 0.05% atropine demonstrated efficacy in controlling gamma zone development.
Second, we identified several risk factors for gamma zone enlargement during atropine treatment, including lower atropine concentration, female sex, larger baseline gamma zone area, and AL elongation. Third, we found a direct effect of 0.05% atropine on gamma zone enlargement, independent of AL elongation. Overall, our data provide information that continued treatment of 0.05% atropine may effectively mitigate parapapillary structural alterations along with myopia progression.
Currently, treatment options for reducing PPA development and enlargement are not established. One study conducted by Chan et al32 investigated changes in intraocular pressure and ONH parameters among 35 myopic children treated with 0.25% atropine nightly over an average duration of 15.2 months and observed no significant changes in optic disc area, cup area, and rim area by OCT. However, structural alterations in the parapapillary region were not included in this study.
The long-term assessment study of ATOM1 revealed that at the 20-year follow-up, the final spherical equivalent, AL, and the incidence of myopia-related complications such as macular degeneration, PPA, and optic disc tilt were comparable between the 1% atropine and placebo groups. Similarly, the 10-year follow-up of ATOM2 demonstrated no significant differences in final spherical equivalent, AL, or the presence of PPA among the 0.05%, 0.1%, and 0.01% atropine treatment groups.33 Nonetheless, the identification of ocular complications was graded based on fundus photographs, which may not capture subtle structural changes as effectively as OCT. In addition, the effects of topical atropine on the development and enlargement of gamma zone were not addressed in this study.
Our study revealed that 0.05% atropine, female sex, baseline gamma zone area, and axial elongation could have an independent effect on gamma zone enlargement during treatment. While in the washout group, younger age, longer AL, and a larger gamma zone at treatment cessation were associated with a more pronounced rebound effect in gamma zone enlargement. Notably, the cumulative gamma zone enlargement in the switch-over group was greater than that observed in the 0.05% washout subgroup, despite both groups having been administered 0.05% atropine eye drops for 2 years and placebo eye drops or a washout period for 1 year.
These findings indicate that early intervention with atropine may offer greater protective benefit in mitigating the expansion of the parapapillary gamma zone.
Previous research34,35 have demonstrated that the presence of parapapillary gamma zone was not associated with AL progression in children and adolescents. In contrast, our results suggest that a larger baseline gamma zone is associated with larger gamma zone enlargement over 3 years. This discrepancy suggests that gamma zone enlargement and AL progression may not occur concurrently during childhood myopia progression.
In addition, mediation analysis indicated that 0.05% atropine treatment had a direct effect on gamma zone changes, accounting for >70% of the total effect. This suggests that a substantial portion of this effect may occur independently of AL elongation, though the intricate associations among topical atropine treatment, axial elongation, and gamma zone development warrant further investigation.
The mechanisms by which atropine influences gamma zone enlargement have not been fully explained. The effects of low-concentration atropine on inhibiting gamma zone enlargement may primarily stem from its impact on the sclera. Scleral hypoxia has been identified as an important contributing factor in myopia development.36,37 Experimental studies indicate that atropine may exert a direct impact on the sclera by reducing both DNA synthesis and glycosaminoglycan production, ultimately mitigating scleral elongation and remodeling.38 Various animal models have shown inhibition of cellular proliferation and extracellular matrix production by atropine within the sclera.39 Excessive axial elongation has been reported to be driven by scleral extracellular matrix remodeling in mammalian models.40,41 Based on these findings, we propose that the direct effects of 0.05% atropine on gamma zone enlargement may reflect its influence on scleral growth and remodeling.
Kim et al introduced the lamina cribrosa/Bruch membrane opening offset theory, proposing that the formation of parapapillary gamma zone is induced by an anterior shift of the lamina cribrosa relative to the retinal layer.42 In this context, it is plausible that atropine could help mitigate the disproportionate growth of sclera and retina, thereby contributing to the overall regulation of gamma zone enlargement and myopia progression. Our results provide new information on the mechanism of atropine's anti-myopia actions. The development and enlargement of parapapillary gamma zone, along with other structural deformations of the ONH, has emerged as a serious concern in the management of myopia.
Such alterations are irreversible and may indicate underlying pathologies related to visual field defects and optic neuropathy. Topical application of low-concentration atropine to mitigate gamma zone enlargement could be an important strategy for preventing future visual impairment in myopic children. However, these findings should be interpreted with caution, as the gamma zone area measured in this study could only serve as an indicator of morphological changes, while the underlying mechanisms and pathways governing these changes have remained elusive so far.
Future studies are warranted to further investigate the effects of atropine on the structure of the sclera and of other biomechanically important elements of the posterior ocular segment in vivo using advanced imaging techniques such as polarization-sensitive OCT.
To our knowledge, this is the first clinical study to report the longitudinal effect of low-concentration atropine eye drops on parapapillary structure changes, based on our ongoing double-masked randomized controlled trial. However, there are several limitations to this study. First, potential selection bias may exist due to the exclusion of children who refused or were unable to cooperate with the OCT ONH examinations.
However, baseline ocular features were largely comparable between the included and excluded participants. Second, the sample sizes for each group were halved due to rerandomization in the LAMP study at the beginning of the third year. While the reduction in sample size might have limited the sensitivity for detecting subtle differences across concentration groups, substantial differences in the gamma zone area were observed.
We also employed generalized estimating equation models to analyze the longitudinal data and adjust for intereye correlations. Third, the placebo group had to be switched to 0.05% atropine treatment during the second year due to ethical concerns. Starting from the third year, the original treatment groups were randomized into a continued treatment subgroup and a washout subgroup.
All participants in the continued treatment groups from the originally studied concentration were switched to 0.05% atropine after the third year. As a result, we could not compare the size changes of gamma zone among 0.05%, 0.025%, and 0.01% atropine with the placebo groups over the full course of 5 years. Fourth, the measurements of gamma zone were manually graded, which could have introduced measurement errors and bias.
However, all images were evaluated by 2 readers independently, and the intergrader and intragrader consistency was found to be excellent. Finally, this is a single-center study; all our participants were Chinese. The applicability of our findings to other ethnic groups may be constrained.
In conclusion, our data suggested that low-concentration atropine applied topically reduced parapapillary gamma zone enlargement along with a concentration-dependent response throughout the treatment period of 3 years. Continued 0.05% atropine treatment could effectively inhibit gamma zone enlargement. These findings provide new information on the effect of 0.05% atropine on mitigating parapapillary structural alterations.